Raf
Las quinasas Raf son componentes clave de la vía de señalización MAPK/ERK, desempeñando un papel crítico en la transmisión de señales desde la membrana celular hasta el núcleo. La activación de Raf conduce a la fosforilación de MEK, que posteriormente activa ERK, influyendo en la división, diferenciación y supervivencia celular. Las mutaciones en Raf, particularmente en B-Raf, están asociadas con varios tipos de cáncer, lo que convierte a Raf en un objetivo crucial en la terapia contra el cáncer. En CymitQuimica, ofrecemos una variedad de inhibidores y moduladores de Raf para apoyar su investigación en oncología, transducción de señales y desarrollo terapéutico.
Se han encontrado 83 productos de "Raf"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MRTX0902
CAS:<p>MRTX0902 is an effective and high selective inhibitor of SOS1 with an IC50 of 46 nM and a Ki of 2 nM.</p>Fórmula:C22H24N6OPureza:99.69%Forma y color:SolidPeso molecular:388.47Sorafenib
CAS:<p>Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57</p>Fórmula:C21H16ClF3N4O3Pureza:98% - 99.89%Forma y color:SolidPeso molecular:464.82Xl-281
CAS:<p>XL-281: potent oral RAF kinase inhibitor, effective on wild-type and mutants, reduces tumor growth and cell proliferation, increases apoptosis.</p>Fórmula:C24H19ClN4O4Pureza:95.77% - 98.83%Forma y color:SolidPeso molecular:462.89Sorafenib tosylate
CAS:<p>Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).</p>Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:99.24% - 99.94%Forma y color:White To Off-White Crystalline PowderPeso molecular:637.03LXH254
CAS:<p>LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.</p>Fórmula:C25H25F3N4O4Pureza:98.3% - 99.92%Forma y color:SolidPeso molecular:502.49Regorafénib N-oxyde (M2)
CAS:<p>Regorafénib N-oxyde M2 is an active metabolite of Regorafenib.</p>Fórmula:C21H15ClF4N4O4Pureza:98.03% - 98.26%Forma y color:SolidPeso molecular:498.81LUT014
CAS:<p>LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.</p>Fórmula:C27H19F3N8OPureza:99.03%Forma y color:SolidPeso molecular:528.49B-Raf IN 2
CAS:<p>B-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research.</p>Fórmula:C20H17F2N5O4SPureza:98.86%Forma y color:SolidPeso molecular:461.44R18
CAS:<p>14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.</p>Fórmula:C101H157N27O29S3Pureza:98%Forma y color:SolidPeso molecular:2309.69SOS1-IN-17
<p>SOS1-IN-17 (Compound 8d) is an orally active inhibitor targeting the SOS1-KRASG12C interaction, with an IC50 of 5.1 nM. It suppresses ERK phosphorylation in DLD-1 cells with an IC50 of 18 nM and demonstrates antiproliferative activity in KRASG12C-mutant Mia-Paca-2 cells, with an IC50 of 0.11 μM. In mouse models, SOS1-IN-17 shows antitumor efficacy against pancreatic cancer.</p>Fórmula:C29H34F3N5O2Forma y color:SolidPeso molecular:541.61Cyclorasin 9A5
CAS:<p>Cyclorasin 9A5 is a cell-permeable, 11-residue cyclic peptide that orthosterically disrupts the Ras-Raf protein interaction, demonstrating an inhibition</p>Fórmula:C75H108FN25O13Pureza:98%Forma y color:SolidPeso molecular:1586.82Cyclorasin 9A5 TFA
<p>Cyclorasin 9A5 TFA is a cell-penetrating cyclic peptide consisting of 11 residues that inhibits the interaction between Ras and Raf proteins, with an IC50 of 120 nM.</p>Fórmula:C75H108FN25O13·xC2HF3O2Forma y color:SolidPeso molecular:1586.82 (free base)Vem-L-Cy5
<p>Vem-L-Cy5 (compound 3), a Vemurafenib-based BRAF inhibitor conjugated with the near-infrared (NIR) fluorophore cyanine-5 (Cy5), selectively targets the BRAF</p>Fórmula:C63H68F5N7O9SPureza:98%Forma y color:SolidPeso molecular:1194.31KG5
CAS:<p>KG5 inhibits PDGFRβ, B-Raf, FLT3, KIT, c-Raf; has anticancer and antiangiogenic effects; Kd: 520 nM (PDGFRβ), 300 nM (PDGFRα).</p>Fórmula:C20H16F3N7OSPureza:98.32%Forma y color:SolidPeso molecular:459.45PROTAC B-Raf degrader 1
CAS:<p>PROTAC B-Raf degrader 1 is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf,PROTAC B-Raf degrader 1 With anti-cancer activity.</p>Fórmula:C36H37N5O12SPureza:98%Forma y color:SolidPeso molecular:763.77SOS1-IN-11
CAS:<p>SOS1-IN-11 is an effective inhibitor of SOS1 (IC50 = 30 nM).</p>Fórmula:C22H24F3N5OPureza:99.4%Forma y color:SolidPeso molecular:431.45MAPK Inhibitor Library
<p>A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;</p>Forma y color:Odour SolidAnti-Phospho-RAF1 (Ser259) Antibody (5X237)
<p>Anti-Phospho-RAF1 (Ser259) Antibody (5X237) is an antibody targeting Phospho-RAF1 (Ser259). Anti-Phospho-RAF1 (Ser259) Antibody (5X237) can be used in ELISA, WB, IHC, IF.</p>Forma y color:Odour LiquidAnti-Phospho-RAF1 (Ser621) Antibody (2K681)
<p>Anti-Phospho-RAF1 (Ser621) Antibody (2K681) is an antibody targeting Phospho-RAF1 (Ser621). Anti-Phospho-RAF1 (Ser621) Antibody (2K681) can be used in ELISA, WB, IF.</p>Forma y color:Odour LiquidRAS GTPase inhibitor 1
CAS:<p>RAS GTPase inhibitor 1 is a RAS GTPase inhibitor with potential antitumor activity.</p>Fórmula:C27H28ClF4N5O2Pureza:98.43%Forma y color:SolidPeso molecular:565.99Anti-Phospho-RAF1 (Ser43) Antibody (8R108)
<p>Anti-Phospho-RAF1 (Ser43) Antibody (8R108) is an antibody targeting Phospho-RAF1 (Ser43). Anti-Phospho-RAF1 (Ser43) Antibody (8R108) can be used in ELISA, IF.</p>Forma y color:Odour LiquidRegorafenib monohydrate
CAS:<p>Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine</p>Fórmula:C21H17ClF4N4O4Pureza:99.69%Forma y color:SolidPeso molecular:500.83ZM 336372
CAS:<p>ZM 336372 is a potent and selective c-Raf inhibitor.</p>Fórmula:C23H23N3O3Pureza:97.24% - 97.51%Forma y color:SolidPeso molecular:389.45GW 5074
CAS:<p>GW 5074 (Raf1 Kinase Inhibitor I)(IC50=9 nM) is an effective and specific c-Raf inhibitor.</p>Fórmula:C15H8Br2INO2Pureza:99.32%Forma y color:SolidPeso molecular:520.94Regorafenib
CAS:<p>Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally</p>Fórmula:C21H15ClF4N4O3Pureza:98% - 99.95%Forma y color:SolidPeso molecular:482.82PLX8394
CAS:<p>Plixorafenib (PLX8394) is an orally active inhibitor of the serine/threonine protein kinase B-Raf (BRAF) protein.Cost-effective and quality-assured.</p>Fórmula:C25H21F3N6O3SPureza:98.75% - >99.99%Forma y color:SolidPeso molecular:542.53Ro 5126766
CAS:<p>RO5126766 (CH5126766) is a dual RAF/MEK inhibitor with IC50 of 8.2 nM, 19 nM, 56 nM, and 160 nM for BRAF V600E, BRAF, CRAF, and MEK1, respectively. Phase 1.</p>Fórmula:C21H18FN5O5SPureza:98.3% - 98.81%Forma y color:SolidPeso molecular:471.46Kobe2602
CAS:<p>Kobe 2602 is an inhibitor of Ras that exhibits anticancer chemotherapeutic activities.</p>Fórmula:C14H9F4N5O4SPureza:98.36% - 99.39%Forma y color:SolidPeso molecular:419.31Agerafenib
CAS:<p>Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.</p>Fórmula:C24H22F3N5O5Pureza:95.78% - 99.23%Forma y color:SolidPeso molecular:517.46Takeda-6d
CAS:<p>Takeda-6d is a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with IC50 of 7.0 nM and 2.2 nM, respectively.</p>Fórmula:C27H19ClFN5O3SPureza:98.27%Forma y color:SolidPeso molecular:547.99AZ304
CAS:<p>AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).</p>Fórmula:C27H25N5O2Pureza:99.82%Forma y color:SolidPeso molecular:451.52TAK-632
CAS:<p>TAK-632 is a potent pan-Raf inhibitor.</p>Fórmula:C27H18F4N4O3SPureza:98% - 99.5%Forma y color:SolidPeso molecular:554.52RAF265
CAS:<p>RAF265 (CHIR-265) inhibits C-Raf/B-Raf/V600E (IC50: 3-60 nM), blocks VEGFR2 (EC50: 30 nM), in Phase 2 trials.</p>Fórmula:C24H16F6N6OPureza:99.56%Forma y color:SolidPeso molecular:518.41AD80
CAS:<p>AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.</p>Fórmula:C22H19F4N7OPureza:99.49% - 99.75%Forma y color:SolidPeso molecular:473.43Raf inhibitor 2
CAS:<p>Raf inhibitor 2 (CID 25014542) is novel inhibitor of Raf kinases.</p>Fórmula:C15H8Br2ClNO2Pureza:98.53%Forma y color:SolidPeso molecular:429.49Encorafenib
CAS:<p>Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.</p>Fórmula:C22H27ClFN7O4SPureza:99.51% - 99.83%Forma y color:SolidPeso molecular:540.01B-Raf IN 11
CAS:<p>B-Raf IN 11 is a novel selective inhibitor.</p>Fórmula:C17H14BrF2N3O3SPureza:99.947%Forma y color:SolidPeso molecular:458.28BAY-293
CAS:<p>BAY-293 is a potent, cell-active SOS1 inhibitor that disrupts the KRAS-SOS1 interaction (IC50: 21 nM).</p>Fórmula:C25H28N4O2SPureza:97.16%Forma y color:SolidPeso molecular:448.58NVP-BHG712
CAS:<p>NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and</p>Fórmula:C26H20F3N7OPureza:97.32% - 98.63%Forma y color:SolidPeso molecular:503.48RAF709
CAS:<p>RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.</p>Fórmula:C28H29F3N4O4Pureza:99.28% - 99.8%Forma y color:SolidPeso molecular:542.55BI-882370
CAS:<p>BI-882370 is a specific RAF kinase inhibitor.</p>Fórmula:C28H33F2N7O2SPureza:97.33% - 99.07%Forma y color:SolidPeso molecular:569.67K-Ras(G12C) inhibitor 9
CAS:<p>K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C).</p>Fórmula:C16H21ClIN3O4SPureza:97.33% - 97.45%Forma y color:SolidPeso molecular:513.78SB-590885
CAS:<p>SB590885 is an effective B-Raf inhibitor (Ki: 0.16 nM, in a cell-free assay).</p>Fórmula:C27H27N5O2Pureza:95.42% - 99.06%Forma y color:SolidPeso molecular:453.54Plx-4032
CAS:<p>Plx-4032 (Vemurafenib) is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.</p>Fórmula:C23H18ClF2N3O3SPureza:98.53% - 99.36%Forma y color:SolidPeso molecular:489.92K-Ras(G12C) inhibitor 6
CAS:<p>Irreversible K-Ras(G12C) inhibitor 6 fully modifies the protein at 10 μM after 24h in vitro.</p>Fórmula:C17H22Cl2N2O3SPureza:89.07% - 97.09%Forma y color:SolidPeso molecular:405.34L-779450
CAS:<p>L-779450, an effective, ATP-competitive Raf kinase inhibitor (IC50: 10 nM) , displays >7, >30 and >70-fold selectivity over p38α, GSK3β and Lck respectively.</p>Fórmula:C20H14ClN3OPureza:≥95%Forma y color:SolidPeso molecular:347.8PLX-4720
CAS:<p>PLX-4720 is a potent and selective B-Raf (V600E) inhibitor designed to block the ATP-binding site of oncogenic B-Raf.Cost-effective and quality-assured.</p>Fórmula:C17H14ClF2N3O3SPureza:97.78% - 99.83%Forma y color:SolidPeso molecular:413.83CCT196969
CAS:<p>CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.</p>Fórmula:C27H24FN7O3Pureza:98.93% - 99.65%Forma y color:SolidPeso molecular:513.52Belvarafenib
CAS:<p>Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF.Cost-effective and quality-assured.</p>Fórmula:C23H16ClFN6OSPureza:98% - 99.65%Forma y color:SolidPeso molecular:478.93I-49 free base
<p>I-49 free base (Pyrido[4,3-d]pyrimidin-7(6H)-one, 2-methyl-4-[[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]amino]-6-(tetrahydro-2H-pyran-4-yl)-) is a novel</p>Fórmula:C23H26ClF3N4O2Pureza:99.64% - 99.88%Forma y color:SolidPeso molecular:482.92
